Welcome to our dedicated page for Vivos SEC filings (Ticker: RDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Inc. filings document formal disclosures for a radiotherapeutic company developing RadioGel® for human applications and IsoPet® for veterinary use. The company’s 8-K reports record material definitive agreements, executive appointments, compensatory arrangements, and governance changes tied to its operating structure.
Regulatory filings also frame RDGL’s public-company disclosures around capital structure, shareholder voting matters, clinical and regulatory updates, and operating and financial results. These records provide the formal context for the company’s radionuclide therapy programs, manufacturing and development activities, and corporate governance matters.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. appointed Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, effective September 1, 2025, with their appointments disclosed on September 15, 2025. Weeks previously served as the company’s Business Development Manager and has a background in medical devices and biotechnology, while Swanberg brings over 35 years of experience in radiochemical processing, medical isotope production, and nuclear technologies.
Under his employment agreement running through December 31, 2027, Weeks will receive a base salary of $192,000 per year plus a $3,000 monthly grant in common stock, issued at the end of each fiscal quarter based on the closing share price, along with customary benefits and expense reimbursement. Swanberg’s consulting agreement runs through December 31, 2028 and provides $12,000 per month in consulting fees plus a $3,000 monthly grant in common stock on the same quarterly pricing basis, with standard confidentiality, non‑competition, and non‑solicitation provisions for both executives.
Vivos Inc. appointed Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, effective September 1, 2025, with their appointments disclosed on September 15, 2025. Weeks previously served as the company’s Business Development Manager and has a background in medical devices and biotechnology, while Swanberg brings over 35 years of experience in radiochemical processing, medical isotope production, and nuclear technologies.
Under his employment agreement running through December 31, 2027, Weeks will receive a base salary of $192,000 per year plus a $3,000 monthly grant in common stock, issued at the end of each fiscal quarter based on the closing share price, along with customary benefits and expense reimbursement. Swanberg’s consulting agreement runs through December 31, 2028 and provides $12,000 per month in consulting fees plus a $3,000 monthly grant in common stock on the same quarterly pricing basis, with standard confidentiality, non‑competition, and non‑solicitation provisions for both executives.
Vivos Inc. reported that its Board of Directors approved the creation of Vivos Scientific India LLP, a wholly owned legal entity based in India. This new subsidiary is intended to establish a manufacturing center, expand the company’s human therapies, and pursue commercialization of those therapies in the Indian market.
The company also plans to use Vivos Scientific India to generate additional human clinical trial data to support its process with the U.S. Food and Drug Administration. This step reflects a strategic focus on both international expansion and building a stronger evidence base for regulatory review.
Vivos Inc. reported that its Board of Directors approved the creation of Vivos Scientific India LLP, a wholly owned legal entity based in India. This new subsidiary is intended to establish a manufacturing center, expand the company’s human therapies, and pursue commercialization of those therapies in the Indian market.
The company also plans to use Vivos Scientific India to generate additional human clinical trial data to support its process with the U.S. Food and Drug Administration. This step reflects a strategic focus on both international expansion and building a stronger evidence base for regulatory review.